Triptorelin: Dosing Protocols

Dosing Overview#

Triptorelin is an FDA-approved pharmaceutical with well-established dosing protocols for each approved indication. Unlike investigational peptides, triptorelin dosing is defined by regulatory-approved prescribing information supported by extensive clinical trial data. All dosing described below reflects approved product labeling and published clinical practice guidelines.

Prostate Cancer Dosing#

Androgen Deprivation Therapy#

Triptorelin is available in three depot formulation durations for prostate cancer, providing flexibility in treatment scheduling.

All formulations achieve castrate testosterone levels (below 50 ng/dL) within 3-4 weeks of initiation and maintain suppression throughout the dosing interval when administered on schedule.

Flare Prevention Protocol#

For the first treatment cycle, an anti-androgen should be initiated to prevent testosterone flare.

1. Begin oral anti-androgen 1 week before first triptorelin injection
   • Bicalutamide 50 mg once daily, or
   • Flutamide 250 mg three times daily
2. Administer first triptorelin depot injection
3. Continue anti-androgen for 2-3 weeks after triptorelin initiation
4. Discontinue anti-androgen once castrate testosterone levels are confirmed

Monitoring Schedule#

Testosterone levels should be checked periodically to confirm sustained castrate levels. A testosterone level above 50 ng/dL during therapy may indicate inadequate suppression, and the dosing interval should be reviewed or shortened.

Endometriosis Dosing#

Standard Protocol#

Triptorelin 3.75 mg intramuscular injection every 28 days for a maximum of 6 months. Treatment should be initiated during the first 5 days of the menstrual cycle to minimize the risk of inadvertent administration during early pregnancy.

Add-Back Therapy#

To reduce hypoestrogenic side effects (particularly bone density loss and vasomotor symptoms), add-back hormone therapy may be initiated with triptorelin.

Options include:

• Norethisterone (norethindrone) 5 mg daily alone
• Low-dose estrogen-progestogen combination
• Tibolone 2.5 mg daily

Add-back therapy has been shown to maintain the therapeutic efficacy of GnRH agonist treatment for endometriosis while significantly reducing bone density loss and vasomotor symptoms.

Treatment Duration Limitation#

Treatment with triptorelin for endometriosis should not exceed 6 months in a single course due to the risk of progressive bone mineral density loss. Retreatment may be considered after an adequate recovery period, but the cumulative effects of repeated courses on bone density should be carefully weighed.

Central Precocious Puberty Dosing#

Pediatric Protocol#

The recommended dose of triptorelin for central precocious puberty is 3.75 mg administered as an intramuscular injection every 28 days. The dose may need adjustment based on the child's weight and clinical response.

Monitoring parameters:

• Pubertal staging (Tanner stage) at each visit
• Height and growth velocity every 3-6 months
• Bone age radiograph every 6-12 months
• LH, FSH, and sex steroid levels to confirm adequate suppression
• Body weight to assess need for dose adjustment

Treatment duration: Treatment continues until the chronologically and skeletally appropriate age for puberty. In girls, this is typically around age 11; in boys, around age 12. The decision to discontinue treatment is based on chronological age, bone age, and psychosocial readiness.

Treatment discontinuation: Upon stopping triptorelin, the HPG axis recovers within weeks to months. Most children resume normal pubertal progression after discontinuation, and studies have demonstrated that treated children achieve adult heights consistent with their genetic potential.

Uterine Fibroids Dosing#

Preoperative Protocol#

Triptorelin 3.75 mg intramuscular injection monthly for 3-6 months before planned surgery.

Goals of preoperative treatment:

• Reduce uterine and fibroid volume by 30-60%
• Correct iron-deficiency anemia from heavy menstrual bleeding
• Facilitate less invasive surgical approaches
• Reduce intraoperative blood loss

IVF Protocol Dosing#

Long Protocol (Pituitary Suppression)#

In controlled ovarian stimulation for IVF, triptorelin is used in a non-depot formulation for pituitary suppression.

1. Begin triptorelin 0.1 mg subcutaneous daily in the mid-luteal phase (approximately day 21 of the preceding menstrual cycle)
2. Continue daily injections until pituitary suppression is confirmed (typically 10-14 days)
3. Begin gonadotropin stimulation (FSH/HMG) while continuing triptorelin at a reduced dose (0.05 mg daily)
4. Continue until HCG trigger for final oocyte maturation
5. Discontinue triptorelin at the time of HCG trigger

Administration Technique#

Depot Injection Preparation#

Triptorelin depot formulations require careful preparation to ensure proper reconstitution and delivery.

1. Verify the correct formulation and dose for the intended indication
2. For microsphere formulations: add the provided diluent to the vial containing the lyophilized microspheres
3. Swirl gently (do not shake vigorously) until a uniform milky suspension forms
4. Withdraw the entire contents of the vial into the provided syringe
5. Attach the injection needle (typically 20-22 gauge, 1.5 inches)
6. Administer by deep intramuscular injection into the gluteal muscle
7. Inject slowly and steadily; do not aspirate after insertion
8. The entire suspension must be injected at once; partial doses will not provide adequate hormone suppression for the full dosing interval

Injection Site Selection#

The dorsogluteal site (upper outer quadrant of the buttock) is the preferred injection site for depot triptorelin. The deltoid may be used for non-depot formulations. Alternate between left and right buttock with successive injections.

Storage#

Storage requirements vary by specific product formulation. In general, store at controlled room temperature (20-25 degrees Celsius) with excursions permitted to 15-30 degrees Celsius for most formulations. Some formulations may require refrigeration (2-8 degrees Celsius). Do not freeze. Protect from light. Check specific product labeling for storage requirements. Reconstituted product should be used immediately and not stored.

Adherence and Timing#

Consistent timing of depot injections is critical for maintaining castrate hormone levels. Delayed injections may allow testosterone to recover above castrate levels, potentially enabling disease progression in prostate cancer patients. Set reminder systems for injection appointments and monitor hormone levels to verify adequate suppression, particularly with extended (3-month and 6-month) depot formulations.

Related Reading#

• Triptorelin overview and research guide
• Triptorelin side effects profile
• Triptorelin research evidence